Company / Free Cash Flow per Share
Halozyme Free Cash Flow per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow per Share
$5.23
FY2025
5-year range
-$0.66 / $5.23
FY2021-FY2025
Trend
+41.7%
vs FY2024
Sector context
#18 of 192
Health Care
What the data says
Among 192 Health Care companies, Halozyme is in the top 9% for free cash flow per share. Free Cash Flow per Share has increased for 4 consecutive years, from $-0.66 in FY2021 to $5.23 in FY2025.
Based on SEC 10-K filings.
5.23 in FY2025 with a 3-year CAGR of +45.2%. Top quartile in the Health Care sector.
Improved from $2.76 to $5.23 over the past 2 years.
Health Care sector context is included.
Free Cash Flow per Share over time
Growth rates
- 3-Year CAGR
- +45.2%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Top 9% in Health CareTop 9% of 192This company $5.23 Sector average $3.32
▼
+57.7% above sector average
Key checks
Key Insights
- Halozyme's free cash flow per share has grown for 4 consecutive years.
- In FY2025, free cash flow per share increased 41.7% year-over-year.
- Ranks #18 out of 192 companies in the Health Care sector.
- Lowest free cash flow per share in the period was in FY2021.
Company context
Key Data Points
- Strong profit margin: 47.9%
- High earnings quality (cash-backed earnings)
- Strong return on equity: 118.2%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash Flow per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $5.23 | +41.7% |
| FY2024 | $3.69 | +33.8% |
| FY2023 | $2.76 | +61.4% |
| FY2022 | $1.71 | +358.3% |
| FY2021 | -$0.66 | -67.2% |
| FY2020 | -$0.40 | -143.2% |
| FY2019 | $0.92 | +341.7% |
| FY2018 | -$0.38 | -137.0% |
| FY2017 | $1.02 | +368.6% |
| FY2016 | -$0.38 | +7.1% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026